• Explore /
  • Poster
  • / BXQ-350: A phase 1b/2 placebo controlled, double blinded study on the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma (mCRC).

BXQ-350: A phase 1b/2 placebo controlled, double blinded study on the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma (mCRC).

Abstract Poster

Authors

null

Reema Anil Patel

University of Kentucky, Lexington, KY

Reema Anil Patel , Ari David Baron , Brian C. Boulmay , Daniel Blake Flora , Julie Anne L Gemmill , Fa Chyi Lee , Davendra Sohal , Grant Richard Williams , Richard Charles Curry III, Michael Gazda , Joseph D. Purvis , Gilles Tapolsky , Ray Takigiku

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

05322590

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr TPS224)

DOI

10.1200/JCO.2024.42.3_suppl.TPS224

Abstract #

TPS224

Poster Bd #

N12

Abstract Disclosures

Similar Posters

First Author: Kanwal Pratap Singh Raghav

First Author: Thomas Jens Ettrich

First Author: Jorge Riera-Knorrenschild

First Author: Thomas Hoehler